Literature DB >> 33238145

A2A Adenosine Receptor Partial Agonism Related to Structural Rearrangements in an Activation Microswitch.

Matthew T Eddy1, Bryan T Martin2, Kurt Wüthrich3.   

Abstract

In drug design, G protein-coupled receptor (GPCR) partial agonists enable one to fine-tune receptor output between basal and maximal signaling levels. Here, we add to the structural basis for rationalizing and monitoring partial agonism. NMR spectroscopy of partial agonist complexes of the A2A adenosine receptor (A2AAR) revealed conformations of the P-I-F activation motif that are distinctly different from full agonist complexes. At the intracellular surface, different conformations of helix VI observed for partial and full agonist complexes manifest a correlation between the efficacy-related structural rearrangement of this activation motif and intracellular signaling to partner proteins. While comparisons of A2AAR in complexes with partial and full agonists with different methods showed close similarity of the global folds, this NMR study now reveals subtle but distinct local structural differences related to partial agonism.
Copyright © 2020 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  G protein-coupled receptors; NMR spectroscopy; drug efficacy; partial agonists

Year:  2020        PMID: 33238145      PMCID: PMC7867584          DOI: 10.1016/j.str.2020.11.005

Source DB:  PubMed          Journal:  Structure        ISSN: 0969-2126            Impact factor:   5.006


  44 in total

1.  Novel short-acting A2A adenosine receptor agonists for coronary vasodilation: inverse relationship between affinity and duration of action of A2A agonists.

Authors:  Z Gao; Z Li; S P Baker; R D Lasley; S Meyer; E Elzein; V Palle; J A Zablocki; B Blackburn; L Belardinelli
Journal:  J Pharmacol Exp Ther       Date:  2001-07       Impact factor: 4.030

2.  Mechanisms of agonist action at D2 dopamine receptors.

Authors:  David J Roberts; Hong Lin; Philip G Strange
Journal:  Mol Pharmacol       Date:  2004-08-31       Impact factor: 4.436

3.  The partial dopamine D2 receptor agonist aripiprazole is associated with weight gain in adolescent anorexia nervosa.

Authors:  Guido K W Frank; Megan E Shott; Jennifer O Hagman; Marissa A Schiel; Marisa C DeGuzman; Brogan Rossi
Journal:  Int J Eat Disord       Date:  2017-03-23       Impact factor: 4.861

4.  5-HT6 receptor agonist and memory-enhancing properties of hypidone hydrochloride (YL-0919), a novel 5-HT1A receptor partial agonist and SSRI.

Authors:  Xiao-Fei Chen; Zeng-Liang Jin; Ying Gong; Nan Zhao; Xiao-Yun Wang; Yu-Hua Ran; You-Zhi Zhang; Li-Ming Zhang; Yun-Feng Li
Journal:  Neuropharmacology       Date:  2018-05-21       Impact factor: 5.250

5.  Myocardial stress perfusion magnetic resonance: initial experience in a pediatric and young adult population using regadenoson.

Authors:  Cory V Noel; Ramkumar Krishnamurthy; Brady Moffett; Rajesh Krishnamurthy
Journal:  Pediatr Radiol       Date:  2016-12-29

6.  Attenuated T2 relaxation by mutual cancellation of dipole-dipole coupling and chemical shift anisotropy indicates an avenue to NMR structures of very large biological macromolecules in solution.

Authors:  K Pervushin; R Riek; G Wider; K Wüthrich
Journal:  Proc Natl Acad Sci U S A       Date:  1997-11-11       Impact factor: 11.205

7.  Discovery of DSP-1053, a novel benzylpiperidine derivative with potent serotonin transporter inhibitory activity and partial 5-HT1A receptor agonistic activity.

Authors:  Hidefumi Yoshinaga; Tomoaki Nishida; Izumi Sasaki; Taro Kato; Hitomi Oki; Kazuki Yabuuchi; Tomohiro Toyoda
Journal:  Bioorg Med Chem       Date:  2018-02-08       Impact factor: 3.641

8.  Single-molecule analysis of ligand efficacy in β2AR-G-protein activation.

Authors:  G Glenn Gregorio; Matthieu Masureel; Daniel Hilger; Daniel S Terry; Manuel Juette; Hong Zhao; Zhou Zhou; Jose Manuel Perez-Aguilar; Maria Hauge; Signe Mathiasen; Jonathan A Javitch; Harel Weinstein; Brian K Kobilka; Scott C Blanchard
Journal:  Nature       Date:  2017-06-07       Impact factor: 49.962

9.  Molecular Determinants of CGS21680 Binding to the Human Adenosine A2A Receptor.

Authors:  Guillaume Lebon; Patricia C Edwards; Andrew G W Leslie; Christopher G Tate
Journal:  Mol Pharmacol       Date:  2015-03-11       Impact factor: 4.436

10.  Effects of 2-bromoterguride, a dopamine D2 receptor partial agonist, on cognitive dysfunction and social aversion in rats.

Authors:  Emilia Tarland; Robert T Franke; Heidrun Fink; Heinz H Pertz; Jan Brosda
Journal:  Psychopharmacology (Berl)       Date:  2017-10-03       Impact factor: 4.530

View more
  5 in total

1.  Slow conformational dynamics of the human A2A adenosine receptor are temporally ordered.

Authors:  Shushu Wei; Naveen Thakur; Arka P Ray; Beining Jin; Samuel Obeng; Christopher R McCurdy; Lance R McMahon; Hugo Gutiérrez-de-Terán; Matthew T Eddy; Rajan Lamichhane
Journal:  Structure       Date:  2021-12-10       Impact factor: 5.006

Review 2.  G Protein-coupled Receptor (GPCR) Reconstitution and Labeling for Solution Nuclear Magnetic Resonance (NMR) Studies of the Structural Basis of Transmembrane Signaling.

Authors:  Haoyi Ge; Huixia Wang; Benxun Pan; Dandan Feng; Canyong Guo; Lingyun Yang; Dongsheng Liu; Kurt Wüthrich
Journal:  Molecules       Date:  2022-04-20       Impact factor: 4.927

3.  Production of a Human Histamine Receptor for NMR Spectroscopy in Aqueous Solutions.

Authors:  Emma Mulry; Arka Prabha Ray; Matthew T Eddy
Journal:  Biomolecules       Date:  2021-04-24

4.  Deciphering conformational selectivity in the A2A adenosine G protein-coupled receptor by free energy simulations.

Authors:  Willem Jespers; Laura H Heitman; Adriaan P IJzerman; Eddy Sotelo; Gerard J P van Westen; Johan Åqvist; Hugo Gutiérrez-de-Terán
Journal:  PLoS Comput Biol       Date:  2021-11-24       Impact factor: 4.475

Review 5.  International Union of Basic and Clinical Pharmacology. CXII: Adenosine Receptors: A Further Update.

Authors:  Adriaan P IJzerman; Kenneth A Jacobson; Christa E Müller; Bruce N Cronstein; Rodrigo A Cunha
Journal:  Pharmacol Rev       Date:  2022-04       Impact factor: 25.468

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.